Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Yanwei Li1,4, Lin Li1, Christian Hölscher2,3

1. Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China
2. Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
3. Second hospital, Shanxi medical University, Taiyuan, Shanxi, PR China
4. Department of human anatomy, Shaoyang Medical College, Shaoyang, Hunan, PR China

Accepted in Reviews in the Neurosciences

running title: incretin drugs can treat neurodegenerative diseases

Corresponding author:

Prof. Lin Li
Key Laboratory of Cellular Physiology,
Shanxi Medical University,
Taiyuan, PR China
Email: linli999@163.com
Abstract

Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance, incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or insulin resistance (IR), may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies, but also have shown first positive results in AD and PD patients in clinical trials. Furthermore, the effects of other related incretin-based therapies, such as GIP agonists, DPP-IV inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

**Keywords:** type 2 diabetes mellitus; insulin resistance; Alzheimer's disease; Parkinson's disease; incretin; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; DPP-IV inhibitors
Introduction

Aside from nutrient digestion and assimilation, the human gastrointestinal tract (GIT) also has significant endocrine functions. To date, the most important endocrine function of the GIT relates to intestinal derived peptides, which are fundamentally involved in postprandial insulin release. This action is termed the “incretin effect”. Only two incretin hormones named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) fulfill the criteria of a true incretin hormone that stimulates glucose-induced insulin secretion of islet beta-cell, and GLP-1 and GIP may be responsible for up to 70% of postprandial insulin secretion (Baggio and Drucker, 2007).

Type 2 diabetes mellitus (T2DM) is a chronic endocrine and metabolic disorder characterized by progressive hyperglycemia, pancreatic β-cell dysfunction and relative insulin deficiency, and insulin resistance in peripheral tissues (Brunetti et al., 2014). The increase of endogenous insulin secretion and reduction of insulin resistance are important targets for antidiabetic drugs. Studies found that the incretin effect is severely reduced in patients with T2DM, which involve deficiency of postprandial insulin secretion (Irwin and Flatt, 2015). Thus, incretin-based therapies have become new class of antidiabetic drugs for treatment of T2DM for their promising action on insulinotropic secretion and improving insulin resistance (Irwin and Flatt, 2015). Currently, two classes of incretin-based therapies are available in the clinic: the GLP-1 receptor agonists and the dipeptidyl peptidase-IV (DPP-IV) inhibitors (Chen et al., 2015a). Moreover, other related incretin-based therapies, including GIP receptor agonists, oxyntomodulin (OXM), dual agonists and tri agonist for incretin receptors, have showed improved treatment effects for T2DM in preclinical studies (Finan et al., 2013, Finan et al., 2015).

Besides anti-hyperglycemic efficacy for T2DM, incretin hormones also promote proliferation/neogenesis of beta cells and prevent their apoptosis, which demonstrate the trophic factor activity of incretins (Kielgast et al., 2011). Moreover, incretin hormones also show additional properties, specifically neurotrophic activity and protective effect, in T2DM-associated neurodegeneration (Hamilton et al., 2011, Salcedo et al., 2012). Recently, studies investigating the effects of incretin-based therapy on neurodegenerative diseases have been published that show very promising results, and may indicate an alternative approach for treating these patients (Perry and Greig, 2004, Harkavyi and Whitton, 2010, Li et al., 2010b, Bak et al., 2011, Mossello et al., 2011, Sakurai, 2011, Luchsinger, 2012, Salcedo et al., 2012, Holscher, 2014a, c, Ji et al., 2016a). In this review, we will primarily discuss the progress of ongoing research on the protection of incretin-based therapy against neurodegenerative diseases.

Insulin resistance and neurodegenerative diseases

As a result of the aging population, neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and Amyotrophic lateral sclerosis (ALS) have been one of the biggest health problems worldwide. However, there is no treatment available to cure these diseases. Because neurons rely more on glucose metabolism than other cell types, bioenergetic deficits have been considered a common cause of neurodegenerative diseases (Cai et al., 2012). Recent pathological investigations have shown that neurodegenerative disorders are associated with impairments in the glucose metabolic pathways, and the incidence of AD, PD, and several other neurologic disorders appears to be higher in persons with T2DM, suggesting that shared mechanisms, such as insulin dysregulation or insulin resistance in the brain, may underlie these conditions (Freiherr et al., 2013, Holscher, 2014d).
Alzheimer’s disease (AD)

AD is a progressive neurodegenerative disorder that affects daily living through memory loss and cognitive impairment and is characterized by the presence of amyloid plaques which are mainly composed of amyloid beta (Aβ) peptide, neurofibrillary tangles and neuronal loss in distinct brain regions, including neocortex and hippocampus. Aging, genetic and environmental factors contribute to its development and progression. Recently, the potential links between AD and T2DM have been identified in several studies (Ott et al., 1999, Kopf and Frolich, 2009, Holscher, 2014c). Both T2DM and AD are age-related chronic diseases. Some epidemiological investigations demonstrated that T2DM increases the risk of developing AD by approximately two-fold, and patients with AD are more likely to develop T2DM (Kopf and Frolich, 2009). Interestingly, AD shares some common features with T2D such as ageing related processes, degeneration, high cholesterol levels, metabolic disorders, Aβ aggregation (Ashraf et al., 2014), glycogen synthase kinase-3 (GSK-3) hyper activity (Gao et al., 2012), deregulated tau protein phosphorylation (Takalo et al., 2014), blood vessel abnormalities, increased oxidative stress, increased inflammatory response, correlation with apolipoprotein E ε4 allele (To et al., 2011) and glyceraldehyde derived advanced glycation end products (Li and Holscher, 2007).

Most notably, it has been shown that an impaired cerebral glucose metabolism is detected at early stages in AD (Cohen and Klunk, 2014), and brain levels of insulin and functional insulin receptors (IR) are lower in AD (Moloney et al., 2010, Talbot et al., 2012). Insulin signaling impairments have been documented in both the brains of AD patients and animal models (Moloney et al., 2010, Holscher, 2011, Long-Smith et al., 2013). In AD patients, brain insulin resistance also occurs independently of diabetes or peripheral insulin resistance, and molecular markers of insulin resistance co-localize with Aβ oligomers and tau inclusions in AD brains (Yarchoan et al., 2014), which suggest that brain insulin resistance is likely a consequence of Aβ pathology. It has already been shown that Aβ oligomers downregulate insulin receptors in primary cortical neurons (Zhao et al., 2008) and induce insulin resistance in cultured hippocampal neurons (Ma et al., 2009). Furthermore, brain insulin signaling is particularly important for learning and memory (Townsend et al., 2007, Freiherr et al., 2013), and provides a physiological defense mechanism against oligomer-induced synapse loss (De Felice et al., 2009), and furthermore protects neurons from accumulation of hyperphosphorylated tau (Escribano et al., 2010), suggesting that insulin resistance may contribute to cognitive deficits in AD. Therefore, some authors have even proposed AD as a “Type 3 diabetes mellitus” limited to central nervous system (CNS) (Lester-Coll et al., 2006), though insulin insensitivity in the AD brain is not linked to high glucose levels. Thus, targeting brain insulin signaling for the treatment of cognitive impairment and AD has now attracted much attention in the field of AD drug discovery (Holscher, 2014d, Chen et al., 2016). In a series of small clinical trials in patients with mild cognitive impairment/AD, nasal application of insulin or long-lasting insulin analogs showed improvements in memory tasks, cerebrospinal fluid biomarkers, and other key biomarkers (Freiherr et al., 2013, Holscher, 2014b). With brain insulin resistance, however, insulin itself may not be the best choice, as it enhances insulin resistance, and other drugs that improve insulin sensitivity may be a better choice (Holscher, 2014b).

Parkinson’s disease (PD)

Recently, studies have shown a link between T2DM and PD, another common chronic neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the degeneration of projecting nerve fibers in the striatum (Xu et al., 2011, Aviles-Olmos et al., 2013b). Both T2DM and PD are age-related chronic diseases. Clinical data analyses confirmed that an 8-30 percentage of PD patients were diabetic, a significantly higher percentage compared to age matched controls (Hu et al., 2007, Miyake et al., 2010, Cereda et al., 2011). Furthermore, abnormal glucose tolerance has been reported in >50% of PD patients (Schernhammer et al., 2011). PD and diabetes also share several genetic
susceptibilities, such as single nucleotide polymorphisms in the growth factor signaling kinase gene Akt, which increase an individual’s risk for developing PD and diabetes (Xiromerisiou et al., 2008). Common pathways that link PD, diabetes, and inflammation have been identified by genome-wide transcriptome profiling (Moran and Graeber, 2008). A study has established that ida-1 (islet cell diabetic autoantigen) is an important modulator in Daf-2/Daf-16 insulin-like signaling pathway and possibly a common link between PD and diabetes (Fatima et al., 2014). Thus, some pathogenic processes may underlie both conditions, and insulin desensitisation may be a common mechanism.

Recent studies have provided evidence that insulin desensitization may exist in PD. An earlier study had found that there is a loss of insulin receptor immunoreactivity in the SNpc neurons in PD, and a dysfunction of the insulin/insulin receptor system may precede death of the dopaminergic neurons (Moroo et al., 1994).

Furthermore, increased IRS2 phosphorylation, a marker of insulin resistance, was found in the basal ganglia of the 6-hydroxydopamine (6-OHDA) lesion rat model of PD (Morris et al., 2008). Moreover, in a high-fat-diet rat model of early-stage T2DM, insulin resistance impairs nigrostriatal dopamine function, indicating that dopaminergic signalling is compromised in T2DM (Morris et al., 2011). The findings are consistent with another study which showed high-fat diet exacerbated MPTP-induced dopaminergic degeneration in mice (Bousquet et al., 2012). In addition, α-synuclein pathology of PD can be induced solely by increased high blood glucose in diabetic animal models (Fatima et al., 2014). Moreover, In preclinical studies, systemic administration of drugs for T2DM, such as insulin (Holscher, 2014d), rosiglitazone (Schintu et al., 2009), and metformin (Patil et al., 2014), significantly attenuate pathological manifestations, including the loss of SNpc neurons and the striatal dopaminergic fibers, microglial activation, or the expression of pro-inflammatory cytokines. In light of these recent findings, a hypothesis has emerged that suggests that mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, and alterations in metabolism may lead to insulin resistance and, ultimately, to diabetes and/or neurodegeneration (Santiago and Potashkin, 2013) (Lima et al., 2014). Hence, the treatment to improve insulin resistance for T2DM may be useful for PD patients (Athauda and Foltynie, 2016).

**Huntington's disease (HD)**

Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an increased number of CAG repeats in the HTT gene which codes huntingtin protein. Apart from neurological impairments, the disease is also accompanied by progressive weight loss and poor glycemic control (Aziz et al., 2007, Aziz et al., 2010). Clinical data showed that patients with HD develop diabetes mellitus (DM) approximately 7 times more often than matched control participants (Farrer, 1985). An early study reported that abnormal glucose tolerance and decreased insulin secretion exists in HD (Podolsky and Leopold, 1977), and glucose metabolism is impaired in both brain and periphery (Petersen and Bjorkqvist, 2006, Powers et al., 2007). Moreover, Impaired glucose tolerance was showed in the R6/1 transgenic mouse model of HD (Josefsen et al., 2008), and transgenic mice eventually become diabetic (Hurlbert et al., 1999). Furthermore, impairment in insulin secretion capacity, a simultaneous decrease in insulin sensitivity, and an increase in the insulin resistance level was found in normoglycemic patients with HD (Lalic et al., 2008). Proteomic analysis of the human brain in HD indicated pathogenesis by molecular processes linked to T2DM (Schonberger et al., 2013). Although the “diabetic-like” condition in the HD mice is not improved by treatment with hypoglycemic agents (Hunt and Morton, 2005), antidiabetic treatment significantly prolonged the survival time of male HD mice (Ma et al., 2007). Hence, antidiabetic drugs may be protective agents for therapeutic intervention in HD patients.

**Amyotrophic lateral sclerosis (ALS)**
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by a selective degeneration of upper and lower motor neurons. Glucose intolerance and insulin resistance has been reported in a significant percentage of patients with ALS (Reyes et al., 1984, Perurena and Festoff, 1987, Pradat et al., 2010), and insulin desensitization is related to disease severity (Harris et al., 1986). A recent systematic review also revealed that ALS was associated with diabetes mellitus (Lekoubou et al., 2014). However, whether there is a causal relationship between glucose homeostasis abnormalities and ALS is controversial (Sun et al., 2015). Moreover, two anti-diabetic drugs, metformin and pioglitazone, seem to have no beneficial effect in the SOD1(G93A) mouse model of ALS (Kaneb et al., 2011) and a clinical trial (Jawaid et al., 2014) (Dupuis et al., 2012). However, another class of anti-diabetic drugs, GLP-1 analogs, has demonstrated neuroprotection against Kainate-induced excitotoxicity and trophic-factor withdrawal in SOD-1 in vitro and in vivo models (Lim et al., 2010, Li et al., 2012b, Sun et al., 2013).

Within this context, the use of antidiabetic drugs used to ameliorate hyperglycemia and insulin desensitization has been proposed as a potential therapy for several neurodegenerative diseases. Indeed, new strategies are being developed to inhibit pathologic hallmarks, such as the use of the incretin hormones as a new treatment for AD, PD, and other neurodegenerative diseases.

GLP-1

**GLP-1 expression in the periphery**

GLP-1 is a 30-amino acid peptide, which is derived from preproglucagon molecule and is secreted by intestinal endocrine epithelial L-cells. It is released in response to meal intake. The majority of circulating “bioactive GLP-1” is in the form of GLP-1(7-36)amide (Baggio and Drucker, 2007). GLP-1(7-36) has an extremely short half-life in the blood (<2 min) and is rapidly cleaved into its “inactive” truncated form, GLP-1(9-36)amide, by the ubiquitous proteolytic enzyme DPP-IV (Baggio and Drucker, 2007).

The actions of GLP-1 are mediated by GLP-1R, a 7-transmembrane spanning protein that belongs to the class B1G-protein-coupled receptor family, which is highly expressed on islet beta cells (Doyle and Egan, 2007, Holscher and Li, 2010). By the binding with GLP-1R of islet, GLP-1 evokes robust insulin-releasing and antihyperglycaemic effects. GLP-1 also promotes beta-cell proliferation and islet cell neogenesis as well as inhibiting beta-cell apoptosis and alpha-cell glucagon secretion. GLP-1R is also expressed widely in the nonislet cells, including heart, intestine, immune cells, kidney, and brain, and exerts indirect metabolic actions. These actions include inhibiting gastric emptying, increasing insulin sensitivity in peripheral tissues, suppression of appetite and reducing bodyweight (Campbell and Drucker, 2013). In addition, GLP-1 also shows improving endothelial function, decreasing inflammation and cardioprotective role (Seufert and Gallwitz, 2014).

**GLP-1 analogues and T2DM**

Given this advantageous biological action profile in glucose homeostasis, GLP-1 is a potent T2DM treatment. However, the short half-life of native GLP-1 limits its application. To overcome this problem, GLP-1 analogues resistant to degradation by DPP-IV have been developed by three different strategies. The first strategy exploits a naturally occurring protein, exendin-4 (originally isolated from the saliva of the lizard Heloderma suspectum), which activates the GLP-1R with equal potency as native GLP-1 (exenatide (Faludi et al., 2009) and lixisenatide (Petersen and Christensen, 2013)). The second strategy exploits the structure of native GLP-1, with a few amino acid alterations that protect the molecule from being degraded by DPP-4 (taspoglutide (Dong et al., 2011)). The third strategy is to slower absorption and to reduce renal elimination by fusion with
larger carrier molecules like albumin (albiglutide (Tomkin, 2009, Trujillo and Nuffer, 2014)) or Fc fragments of immunoglobulin G (dulaglutide (Scheen, 2016)), or by attachment of a fatty-acid side-chain which allows reversible binding to albumin (liraglutide (Vilsboll, 2009) and semaglutide (Lau et al., 2015)). Besides this, incorporation of the molecules in injectable microspheres (exenatide once-weekly) is a viable strategy to extend drug duration. Table 1 shows several novel enzyme-resistant, long-acting GLP-1 analogues which have been approved and are on the market as a T2DM treatment (Jendle et al., 2012), or which have shown good effects in preclinical and clinic trails. These GLP-1 agonists are currently used as second-line therapies in type 2 diabetes mellitus, or in triple therapy regimens, and are also applied for first-line use in the case of intolerance or contraindications to metformin(Inzucchi et al., 2015). Moreover, GLP-1 analogues have a favorable safety profile and a low risk of hypoglycemia (Nauck, 2011).

**GLP-1 in the brain**

Within the brain, a small amount of GLP-1 is produced in the nucleus of the solitary tract in the caudal brainstem (Merchenthaler et al., 1999, Salcedo et al., 2012, Ohshima et al., 2015). Besides these neurons, microglia also may express and secrete GLP-1, and expression and secretion are stimulated by cAMP and dependent on the microglial activation state (Kappe et al., 2012). Peripheral GLP-1 also can cross the blood-brain barrier into the brain, or communicate with the brain via sensory afferent vagal neurons (Hunter and Holscher, 2012, Cork et al., 2015). The GLP-1R is also expressed widely in the CNS, including the hypothalamus, cortex, hippocampus, striatum, substantia nigra and brain stem, as well as the subventricular zone (Merchenthaler et al., 1999, Hamilton and Holscher, 2009, Cork et al., 2015). Under normal physiological conditions, its expression is primarily confined to large output neurons, epitomized by pyramidal and dentate granule neurons as well as Purkinje cells, where, in particular, it localizes to dendrites and on or near synapses (Cork et al., 2015).

By binding to GLP-1R in the brain, GLP-1 may act as an anorectic neurotransmitter, regulates glucose homeostasis, lowers core body temperature and plays a role in the activation of the central stress responses (Vrang and Larsen, 2010). Moreover, within the brain GLP-1 appears to have additional effects that are not directly related to glucose metabolism. Recent studies have demonstrated that exogenous administration GLP-1 or its analogues can promote cell proliferation, neuronal differentiation and neurite outgrowth, and enhance synaptic plasticity, strengthen long-term potentiation (LTP), improve cognitive performance (Gault and Holscher, 2008a, Holst et al., 2011), in accord with GLP-1R over-expression mice exhibiting increased neurite growth and improved learning (During et al., 2003) and knockout with impaired memory formation (Abbas et al., 2009). In vitro studies have shown that GLP-1 or its analogues protected against nerve cell apoptosis induced by several neurotoxic substances including H$_2$O$_2$ (Perry et al., 2002a), glutamate (Perry et al., 2002b), iron (Perry et al., 2003), Aβ (Perry et al., 2003, Li et al., 2010a) and methyl glyoxal (Kimura et al., 2009, Sharma et al., 2013). Other authors have observed GLP-1R expression also on glial cells (microglia and astrocytes), proposing a role for them as modulators of CNS inflammation (Iwai et al., 2006).

**The effects of GLP-1 on neurodegenerative disease**

In view of the potent neurotrophic and neuroprotective actions of GLP-1, several enzyme-resistant, long-acting GLP-1 analogues had been tested in different animal models of AD. In the APP/PS1 AD mouse model, liraglutide (McCLean et al., 2011, Long-Smith et al., 2013), lixisenatide (McCLean and Holscher, 2014b), exendin-4 (Li et al., 2010a), Val(8)GLP-1 (Gengler et al., 2012), and geniposide (Zhang et al., 2015b), a GLP-1R agonist extracted from gardenia fruit, decreases desensitization of insulin receptor, soluble Aβ oligomers, amyloid plaque load, astrocytosis and inflammatory reactions. The treatment also prevents memory...
Incretin drugs can treat neurodegenerative diseases

impairments, synapse loss, and deterioration of synaptic plasticity in the hippocampus (Gault and Holscher, 2008a, McClean et al., 2010, McClean and Holscher, 2014a). Furthermore, in an AD rat model induced by intrahippocampal injection of Aβ, liraglutide (Han et al., 2013) and Val(8)GLP-1(Wang et al., 2010, Wang et al., 2013) activates cAMP signaling in the brain and protects the rats against the Aβ-induced impairments of spatial memory and deficit of LTP in a dose dependent manner. In the rodent model of sporadic AD by intracerebroventricularly injection with streptozotocin (STZ), liraglutide (Xiong et al., 2013), exendin-4 (Chen et al., 2012), Val(8)GLP-1 (Li et al., 2012a) and geniposide (Gao et al., 2014) decrease hyperphosphorylation of tau and neurofilament proteins. In the P301L mouse model of tauopathy, liraglutide furthermore reduced the levels of tangles and hyperphosphorylated tau (Hansen et al., 2015). All in all, these experimental studies in AD animal models have found beneficial effects of GLP-1-based therapies on cognition, synaptic plasticity and metabolism of Aβ and tau protein phosphorylation.

Besides better therapeutic potential for AD, long-acting GLP-1 analogues had been tested in several animal models of PD. In a rat model of PD induced by 6-OHDA injection into the brain, exendin-4 has shown protection of dopaminergic neurons in the substantia nigra and prevention of dopamine loss in the basal ganglia while preserving motor control (Bertilsson et al., 2008). Moreover, exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of PD with combined noradrenergic and serotonergic lesions (Rampersaud et al., 2012). Furthermore, some authors also found that MPTP-treated mice, another typical PD mice model, were protected by exendin-4 (Li et al., 2009), Val(8)GLP-1-glu-PAL(Zhang et al., 2015a), liraglutide (Liu et al., 2015a), lixisenatide (Liu et al., 2015a) and geniposide (Chen et al., 2015b) against nigrostriatal damage. Thus, GLP-1-based therapies may be used as a possible therapy for the motor and/or non-motor symptoms prominent in the early stages of PD.

In addition, some studies also demonstrated the neuroprotective activity of GLP-1 in both cell culture and in vivo models of ALS. In NSC-19 neuroblastoma cells, exendin-4 elevated choline acetyltransferase (ChAT) activity, increased cell viability, and protected cells from H2O2-induced oxidative stress and staurosporine-induced apoptosis. Additionally, in both wild-type SOD1 and mutant SOD1 (G37R) stably transfected NSC-19 cell lines, which were more vulnerable to oxidative stress, exendin-4 protected against trophic factor withdrawal-induced toxicity. ALS mice (SOD1 G93A mutant mice) treated with exendin-4 showed improved glucose tolerance and normalization of behavior. Furthermore, exendin-4 treatment attenuated neuronal cell death in the lumbar spinal cord; immunohistochemical analysis demonstrated the rescue of neuronal markers, such as ChAT, associated with motor neurons (Li et al., 2012b). Moreover, a study showed that Exendin-4 protects motor neurons against glucosamine-induced cytotoxicity by restoring cellular glucose uptake, glucokinase activity and intracellular ATP levels (Lim et al., 2010). Similarly, N-acetyl-GLP-1(7-34) amide (N-ac-GLP-1), a long-acting, N-terminally acetylated, C-terminally truncated analog of GLP-1, also showed therapeutic potential in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice (Sun et al., 2013). Thus, these neuroprotective effects of exendin-4 and N-ac-GLP-1 support the concept that GLP-1 signaling is neuroprotective and may be a treatment strategy for ALS.

Several studies demonstrated that exendin-4 ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a N171-82Q mouse model of HD. The treatment also improved motor function and extended the survival time of the HD mice (Martin et al., 2009, Martin et al., 2012). These findings demonstrate that GLP-1–based strategies may be a neuroprotective treatment strategy for HD.

Additionally, the anti-inflammation function of GLP-1 may be protective in the treatment of neurodegenerative diseases. Studies showed that exendin-4 can prevent lipopolysaccharide (LPS)-induced cytokine and chemokine mRNA synthesis in both human and mouse monocytes (Arakawa et al., 2010) and also
reduces the increase of microvascular permeability induced by LPS (Dozier et al., 2009). The drug can also reduce TNF-α cytokine release and protect hippocampal neurons in STZ injected rats (Solmaz et al., 2015). Clear effects of exendin-4 in reducing chronic inflammation in a stroke diabetic rat model was found in another study (Darsalia et al., 2012, Darsalia et al., 2014). Chronic inflammation was also reduced by exendin-4 in a Parkinson’s animal model (Kim et al., 2009). Another study also had displayed that liraglutide reduced pro-inflammatory cytokine levels and inhibited chronic inflammation response in the brain induced by exposing the brain to 6 Gy X-ray irradiation (Parthsarathy and Holscher, 2013). Furthermore, several GLP-1 analogues also showed anti-inflammation function in various AD and PD animal models (Li et al., 2009, McClean et al., 2011). Thus, GLP-1 may be a suitable treatment for reducing the chronic inflammatory response in the brain found in several neurodegenerative conditions.

Based on the very encouraging protective properties of GLP-1 analogues, and on the fact that such drugs are already on the market and have shown a good safety profile, several clinical trials have started to test the neuroprotective effects of exenatide or liraglutide in PD or AD patients (Holscher, 2014a). A recent open label pilot study by Aviles-Olmos and colleagues suggests that 12 months of treatment with exenatide improves motor and cognitive symptoms in PD patients (Aviles-Olmos et al., 2013a), and that the effect persists as long as 12 months after termination of the treatment (Aviles-Olmos et al., 2014). A phase II clinical trial testing the once-weekly formulation of exendin-4 is currently ongoing. The drug liraglutide has been shown to protect the brain from the AD disease progression in an 18FDG-PET imaging study. The AD typical reduction of brain activity and energy utilization was prevented by liraglutide, indicating that the drug reversed the insulin resistance in the brain and normalized brain function (Gejl et al., 2016). A phase II clinical trial is currently ongoing (Holscher, 2014a). Thus, GLP-1 analogues show great promise to be helpful in treating a range of neurodegenerative disorders.

**Glucose dependent insulinoctropic polypeptide (GIP)**

**GIP expression in the periphery**

GIP is an endogenous 42 amino acid peptide hormone synthesized in and released from intestinal K-cells (Baggio and Drucker, 2007). GIP initially was named gastric inhibitory polypeptide, based on its ability to inhibit gastric acid secretion. However, subsequent studies revealed that GIP could also stimulate insulin secretion in animals and humans. Because the inhibitory effect of GIP on gastric acid secretion was seen only at pharmacologic doses, whereas its incretin action occurred at physiologic levels, GIP was renamed glucose dependent insulinoctropic polypeptide to reflect its physiologic action yet retain the acronym (Dupre et al., 1973). In humans, basal circulating GIP levels range between 0.06 and 0.1 nmol/L, and increase to 0.2-0.5 nmol/L after a meal (Ross et al., 1977, Orskov et al., 1996). The half-life of intact biologically active GIP is less than 2 minutes in rodents, approximately 7 minutes in healthy individuals and 5 minutes in patients with T2DM, respectively (Deacon et al., 2000). The amino-terminal Tyr1-Ala2 dipeptide of GIP (1-42) is removed producing the metabolite GIP(3-42) by DPP-IV which is ubiquitously expressed in mammalian tissues and organs (Kieffer et al., 1995). GIP in the blood circulation also is rapidly cleared through the kidney (Meier et al., 2004), and the liver also contribute to GIP extraction.

GIP exerts its effects through binding to the GIP receptor (GIP-R), a member of the 7-transmembrane-spanning, heterotrimeric G-protein-coupled receptor superfamily. The GIP-R is widely distributed in the pancreas, stomach, small intestine, adipose tissue, adrenal cortex, pituitary, heart, testis, endothelial cells, bone, trachea, spleen, thymus, lung, kidney, thyroid, and several regions in the CNS (Baggio and Drucker, 2007). Activation of GIP-R signaling is coupled to increases in cAMP and intracellular Ca²⁺ levels,
as well as activation of PI-3K, PKA, PKB, MAPK, and phospholipase A2 (Baggio and Drucker, 2007). By the binding with GIP-R of islet, GIP potently stimulates insulin secretion similar to its sister hormone GLP-1 (Kim et al., 2005). Besides its insulinotropic activity, GIP exerts a number of additional actions including promotion of growth (Trumper et al., 2001), survival (Trümper et al., 2002), differentiation and proliferation of the pancreatic beta-cell (Marenah et al., 2006). In addition, GIP possesses glucose-lowering extrapancreatic effects, including inhibition of hepatic glucose production, promotion of glucose uptake in isolated muscle, and reduction of hepatic insulin extraction (Seino and Yabe, 2013). GIP receptors have been localized to rodent and human α-cells, and GIP infusion also increased plasma levels of glucagon and enhanced glucose excursion during a meal test in subjects with T2DM (Chia et al., 2009). GIP also plays a role in adipocyte biology and lipid metabolism, including increase of lipoprotein lipase, stimulation of lipogenesis, enhancement of fatty acid, augmentation of insulin-induced fatty acid incorporation and inhibition of both glucagon- and adrenergic-receptor-mediated lipolysis (McIntosh et al., 2009), which ensures efficient deposition of fat in body stores. Moreover, GIP receptors are expressed by osteoclastic cells in bone, activation GIP receptors may promote bone formation in mice (Bollag et al., 2001, Tsukiyama et al., 2006, Zhong et al., 2007, Nissen et al., 2014). GIP-receptor mRNA has been detected in the rat adrenal cortex. GIP exerts a moderate stimulatory effect on basal glucocorticoid secretion (Mazzocchi et al., 1999).

**Modification of GIP analogues**

Notably, the unfavourable pharmacokinetic profile and the weak biological effects of native GIP limit its effectiveness in the clinic. To overcome this, longer-acting GIP agonists exhibiting enzymatic stability and enhanced bioactivity have been generated. Due to enzymatic degradation in vivo by DPP IV, the most specific pharmacological approach for GIP would be modification at the N-terminus to disrupt DPP IV-mediated degradation. In addition, for being rapidly cleared through the kidney (Meier et al., 2004), it also is an alternative approach by binding with fatty acid derivatization or polyethylene glycol (PEG) to delay renal extraction of GIP. Indeed, it has been shown that these modified GIP analogues are not cleaved by DPP-IV, resulting in enhanced potency in vitro and greater insulinotropic and antihyperglycaemic activities in an animal model of T2DM compared to the native peptide (Irwin and Flatt, 2009).

1. Several novel Tyr1-modified GIP analogues have been developed, including N-acetyl-GIP (Ac-GIP), N-pyroglutamyl-GIP (pGlu-GIP) (O’Harte et al., 2002), N-Fmoc-GIP (where Fmoc is 9-fluorenylmethoxycarbonyl), N-palmitate-GIP (Gault et al., 2002), N-gluticol-GIP (Green et al., 2005) (O’Harte et al., 1999) (O’Harte et al., 2000).

2. A series of Ala2-substituted GIP analogues has been synthesised, including (Abu2 (2-aminobutyric acid))GIP, (Sar2(2-sarcosine))GIP (Gault et al., 2003b), (Gly2)GIP (Gault et al., 2003a), (Ser2)GIP (Gault et al., 2003a) and (d-Ala2)GIP (Hinke et al., 2002).

3. By binding through fatty acid derivatization in C-terminal to delay renal extraction of GIP, several long-acting GIP analogues have been designed. These include GIP(Lys37PAL), GIP(Lys16PAL) (Irwin et al., 2006), N-AcGIP(Lys37PAL), N-AcGIP(Lys16PAL) (Irwin et al., 2005a), N-pGluGIP(Lys37PAL), N-pGluGIP(Lys16PAL) (Irwin et al., 2005b) and (d-Ala2)GIP-glu-PAL (Li et al., 2016).

4. Through conjugation with PEG to prolong the in vivo half-life of GIP, Gault et al design a novel C-terminal mini-PEGylation of GIP (GIP[nPEG]) (Gault et al., 2008). And dual modification of a shortened version of GIP, GIP(1–30) by N-terminal acylation and C-terminal PEGylation, had been generated (Salhanick et al., 2005).

**GIP and T2DM**
Due to potent insulinotropic effect of GIP, GIP may be promising as an attractive agent for the treatment of T2DM. On this point, however, there are a lot of disagreements. On the one hand, majority authors deem that GIP was not suitable for T2DM patients. Because in most T2DM patients, the secretion of GIP is near normal, but its effect on insulin secretion, particularly in the late phase is severely impaired. A study found that β cell GIP-R is transcriptionally upregulated by PPAR-γ, and GIP-R mRNA transcripts are reduced in islets from PPAR-γ -/- mice, potentially linking glucotoxicity to reduced PPAR-γ activity and decreased GIP-R expression (Gupta et al., 2010). Hence, it seems obvious that there is a resistance to the insulinotropic action of native GIP in T2DM patients. Moreover, in a clinical trial, although GIP induced an early postprandial increase in insulin levels, GIP also induced an early postprandial augmentation in glucagon, a significant elevation in late postprandial glucose, and a decrease in late postprandial GLP-1 levels (Chia et al., 2009). With a concomitant increase in glucagon, the glucose-lowering effect of GIP was lost. Native GIP infusion further worsened hyperglycemia postprandially, most likely through its suppressive effect on GLP-1. Thus, these findings make it unlikely that GIP or GIP-R agonists will be useful in treating the hyperglycemia of patients with T2DM. Furthermore, some author has proposed using GIP receptor antagonism to treat T2DM patients (Gault et al., 2005) (Sparre-Ulrich et al., 2016) and antagonizing GIP action may be a good therapeutic strategy for diabetes related obesity.

On the other hand, recent studies support the application of GIP in treatment of T2DM patients (Finan et al., 2016). A study has shown that the reduction of hyperglycaemia with insulin in T2DM subjects restores GIP-stimulated insulin secretion (Hojberg et al., 2009). Furthermore, the administration of sulphonylurea to induce K_{ATP} channel closure has been shown to ameliorate the impaired insulinotropic effect of GIP in patients with T2DM. Overall, this work suggests that the augmentation of GIP action is an appropriate goal for the treatment of T2DM, especially in combination with other glucose-lowering drugs (Irwin and Flatt, 2009). GIP overexpressing Tg mice demonstrated enhanced β-cell function, resulting in improved glucose tolerance and insulin sensitivity, they exhibited reduced diet-induced obesity. Reduced adiposity in GIP Tg mice was associated with decreased energy intake, involving overexpression of hypothalamic GIP. Together, these studies suggest that, in the context of over-nutrition, transgenic GIP overexpression has the potential to improve hepatic and adipocyte function as well as glucose homeostasis (Kim et al., 2012).

To date, there are limited clinical data regarding GIP-based therapeutics in T2DM. Thus, more detailed clinical trials with large cases are needed to discover the true therapeutic promise of GIP-related peptide drugs.

The effects of GIP on neurodegenerative diseases

In the central nervous system, GIP is expressed in neurons and acts as a neurotransmitter, and GIP-R are also found in multiple brain regions, including the olfactory bulb, hippocampus, cerebellum, cerebral cortex, amygdala, substantia nigra, thalamus, hypothalamus, and brainstem (Nyberg et al., 2005, Nyberg et al., 2007). Recent studies have shown that application of stable GIP analogues such as D-Ala2-GIP or Pro3-GIP by peripheral administration can cross the BBB, and activation of the GIP-R leads to proliferation of neuronal progenitor cells (Holscher, 2014c). Therefore GIP may contribute to neurogenesis. GIP not only has growth-factor like properties in the brain, but also modulates synaptic activity. GIP prevented the detrimental effects of Aβ on synaptic plasticity (LTP) in the hippocampus (Gault and Holscher, 2008b) and on spatial learning and memory during the water maze task (Figueiredo et al., 2011). Furthermore, GIP has been shown to promote axonal regeneration after sciatic nerve injury (Buhren et al., 2009). In our previous study, chronic injection of D-Ala2GIP enhanced memory formation, synaptic neurotransmission (LTP) in the hippocampus, and progenitor cell proliferation in the dentate gyrus of wild type (WT) mice and mice on a high-fat diet without inducing adverse side effects (Porter et al., 2011, Faivre et al., 2012). Moreover, D-Ala2GIP can improve
cognitive function and prevent deficits of learning and memory in APP/PS1 transgenic mice, and reduces the Aβ plaque load and neuro-inflammation in the brain. Synaptic plasticity and synapse numbers were also normalized by the drug (Duffy and Holscher, 2013, Faivre and Holscher, 2013b, a). In our other study, the results demonstrate that treatment with D-Ala2-GIP-glu-PAL significantly inhibits MPTP-induced Parkinsonism-like behaviour of mice. D-Ala2-GIP-glu-PAL also reduces MPTP-induced damage in the dopaminergic neurons in mice model. Moreover, neuroprotective activity of D-Ala2-GIP-glu-PAL may, at least partially, result from increasing CREB-mediated Bcl-2 expression to prevent apoptosis and from the reduction of chronic neuro-inflammation (Li et al., 2016). Growth factor like agents such as long-acting GIP analogues hold promise of novel treatments that not only improve the symptoms but prevent the neurodegenerative processes underlying PD. Overall, these properties make GIP analogues a promising target for the development of novel treatments of AD and PD (Ji et al., 2016a).

DPP-IV inhibitors

DPP-IV, also known as adenosine deaminase complexing protein 2 (ADCP2), adenosine deaminase binding protein (ADABP), TP103 protein, and T cell activation antigen CD26, is a serine peptidase found in numerous sites, including the kidney, intestinal brush-border membranes, hepatocytes and vascular endothelium. In addition, DPP-IV is also expressed on a specific set of T lymphocytes and is thought to contribute to T-cell activation and proliferation. Solubilized DPP-IV is also found in body fluids such as blood plasma and cerebrospinal fluid. DPP-IV can selectively cleave off the N-terminal dipeptides from peptides with proline or alanine in the second amino acid position (Lambeir et al., 2003). As discussed above, this enzyme activity of DPP-IV has been implicated in the regulation of the biological activity of the insulinotropic peptides GLP-1 and GIP. In contrast, DPP-IV inhibition was demonstrated to protect GLP-1 and GIP from degradation, again resulting in enhanced insulinotropic activity of GLP-1 and GIP (Deacon et al., 2001). DPP-IV has other key substrates such as IGF-1 and other growth factors (Mentlein, 1999).

DPP-IV inhibitor and T2DM

A series of preclinical experiments and clinical trials have demonstrated that DPP-IV inhibitors are effective in enhancing endogenous levels of GLP-1 and GIP, resulting in enhanced insulin secretion, improved glucose tolerance and pancreatic islet cell function in animal models and patients of T2DM (Marguet et al., 2000). These findings have resulted in eight commercially available DPP-4 inhibitors, including alogliptin (Nesina®, Vipidia®)(Keating, 2015, Takeda et al., 2016), anagliptin (Yang et al., 2015), gemigliptin (Zemiglo®)(Kim et al., 2013, Jung et al., 2014), linagliptin (Forst and Pfutzner, 2012, Barnett, 2015), saxagliptin (Gault et al., 2015, Anderson et al., 2016), (Januvia®), Xelevia™, Glactiv(®), Tesavel(®))(Garg et al., 2013, Plosker, 2014), teneligliptin (Nakamaru et al., 2015), and vildagliptin (Galvus®, Novartis AG) (Mikhail, 2008, Richter et al., 2008), being approved and entering into the clinic (Chen et al., 2015a). These DPP-IV inhibitors have good oral bioavailability and a relatively long duration of action in patients with T2DM. DPP-IV inhibitors may be used as monotherapy or in double or triple combination with other oral glucose-lowering agents such as metformin, thiazolidinediones, and sulfonylureas (Chen et al., 2015a).

Long-term studies with the DPP-IV inhibitors in clinical development have, to date, proved these to be safe and well tolerated and not to be associated with adverse immune effects (Garg et al., 2013). Due to sustained DPP-IV enzyme inhibition and a long half-life, the majority of DPP-IV inhibitors are generally prescribed once a day. Therefore, DPP-IV inhibitors have become accepted in clinical practice due to their excellent tolerability profile, with a low risk of hypoglycemia, a neutral effect on body weight, and once-daily dosing (Chen et al.,
incretin drugs can treat neurodegenerative diseases

2015a).

Fig. 2 chemical structures of clinically approved DPP-IV inhibitors (Chen et al., 2015a)

The effects of DPP-IV inhibitors on neurodegenerative diseases

Most DPP-IV inhibitors do not pass the blood-brain barrier, with some exceptions (Nassar et al., 2015), but DPP-IV inhibition increases circulated GLP-1 and GIP, which are the blood brain barrier permeable ligands (Kastin et al., 2002). Thus, it is unsurprising to find CNS action of DPP-IV inhibitors. Recently, the neuroprotective properties of several DPP-IV inhibitors have been shown in cell cultures and animal models (Matteucci and Giampietro, 2015). Notably, saxagliptin recently showed an ameliorating efficacy in the STZ-induced AD model. Saxagliptin treatment improved hippocampal GLP-1 levels and memory retention, attenuated Aβ burden, tau phosphorylation, inflammatory markers (Kosaraju et al., 2013a). In a rat PD model induced by rotenone (ROT), saxagliptin prominently improved motor functions denoting antiparkinsonian efficacy via antioxidant, anti-inflammatory, antiapoptotic, neuroprotective and neurorestorative mechanisms (Nassar et al., 2015). In addition, saxagliptin also evoked neurogenesis indicated by BDNF enhancement. In addition, another DPP-IV inhibitor, vildagliptin, effectively restored neuronal IR function, increased GLP-1 levels and prevented brain mitochondrial dysfunction, thus attenuating the impaired cognitive function caused by high-fat diet (HFD) (Pipatpiboon et al., 2013) (Pintana et al., 2013). Vildagliptin also restored the loss of hippocampus CA1 dendritic spines, which was associated with cognitive decline caused by HFD (Sripetchwandeewee et al., 2014). Furthermore, vildagliptin ameliorated cognitive deficits and pathology observed in the STZ-induced AD animal model (Kosaraju et al., 2013b). In the rat rotenone model of PD, vildagliptin blocked the receptor for advanced glycation end product (RAGE)/nuclear factor-κB (NFκB) cascade, exerting a potential antiparkinsonian effect (Abdelsalam and Safar, 2015). Furthermore, administration of vildagliptin has significantly attenuated impairment of learning, memory, endothelial function, blood brain
incumbent drugs can treat neurodegenerative diseases

barrier permeability and biochemical parameters induced by pancreatectomy (Jain and Sharma, 2015). In addition, sitagliptin also increased brain GLP-1 levels and decreased beta amyloid precursor protein (APP) as well as attenuated Aβ deposit in a transgenic mouse model of AD. Sitagliptin reduced the inflammation and nitrosative stress in the cerebral cortex (D’Amico et al., 2010). In rats with high-sucrose diet-induced metabolic syndrome (MetS), besides its well-known hypoglycemic action, sitagliptin may also have beneficial effects on hyperglycemia-induced vascular changes in an endothelium-dependent manner (Cicek et al., 2014). Sitagliptin significantly improved the metabolic parameters and decreased circulating and brain oxidative stress levels, and completely prevented brain and hippocampal mitochondrial dysfunction and equally improved the learning behaviors impaired by HFD-induced insulin-resistant rats (Pintana et al., 2013). Pterocarpus marsupium (PM, Fabaceae) and Eugenia jambolana (EJ, Myrtaceae) extracts have demonstrated the DPP-IV inhibitory properties (Kosaraju et al., 2014a), and PM and EJ extracts contain cognitive enhancers as well as neuroprotective agents against STZ induced pathology (Kosaraju et al., 2014b). Importantly, DPP-IV show neuroprotective effects independently of GLP-1 activity (Darsalia et al., 2016). Hence, these findings suggested the beneficial roles of DPP-IV inhibitors in AD and PD. Although mechanisms distinct from glycemic control alone have been claimed to account for protection against neuronal degeneration, the precise cellular mechanism by which DPP-IV inhibitors exert their neuroprotective effects remain unknown and need further be investigated (Matteucci and Giampietro, 2015).

**Oxyntomodulin (OXM)**

OXM is a 37-amino-acid peptide generated by post-translational processing of preproglucagon in the gut and is secreted postprandially from L-cells of the jejun-ileum together with other preproglucagon-derived peptides including GLP-1 (Bataille et al., 1982). Peripheral OXM administration reduces food intake and increases energy expenditure in rodents (Dakin et al., 2004) and humans (Wynne et al., 2006). Studies indicate that OXM activity at the GLP-1R is responsible for the reduction in food intake and activity at the glucagon receptor (GCGr) causes weight loss by increasing energy expenditure (Wynne et al., 2006, Kosinski et al., 2012). And it is notable that co-administration of GLP-1 and glucagon in humans can replicate the beneficial actions of OXM (Cegla et al., 2014). Hence, OXM is a natural agonist at both GCGr and the GLP-1R.

**OXM and T2DM**

The dual agonist properties of OXM add additional better effects than sole GLP-1R agonist for T2DM. OXM, like other GLP-1R agonists, stimulates cAMP formation and lowers blood glucose after both oral and ip glucose administration. OXM also directly stimulates insulin secretion from murine islets and INS-1 cells in a glucose- and GLP-1R-dependent manner. In addition, OXM enhances beta-cell function but does not inhibit gastric emptying in mice. Thus, OXM mimics some but not all of the actions of GLP-1R agonists in vivo (Maida et al., 2008). The difference of OXM may result from the activation of GCGr. It is generally recognized that glucagon increases blood glucose and plays an opposite effects different from insulin which decrease blood glucose. Thus, activation of GCGr seems to be a disadvantage for T2DM patients. However, this view has been questioned and challenged recently. A study has shown that transgenic mice overexpressing the GCGr in pancreatic beta-cells demonstrate increased insulin secretion and pancreatic beta-cell mass, with protection against impaired glucose tolerance following high fat feeding (Gelling et al., 2009). Moreover, a 4-week clinical study in obese subjects demonstrated that repeated subcutaneous administration of OXM was well tolerated and caused significant weight loss with a concomitant reduction in food intake (Wynne et al., 2005). As a result, by activating GLP-1 and GCGr, OXM may have superior weight loss and glucose lowering effects, compared to
single GLP-1R agonists, which support the role of OXM as a potential anti-obesity and antihyperglycemic therapy for T2DM patients.

Despite their anti-diabetic and anti-obesity potential, OXM-based therapies have not yet reached the clinic, due to the susceptibility of the native hormone to enzymatic degradation. Native OXM is susceptible to degradation by the enzyme DPP-IV, which lead to the short in vivo half-life (Kervran et al., 1990). Thus, it is necessary to produce long-lasting analogues for clinical use. As discussed above, substitution of the naturally occurring -Ala at position 2 in incretin results in DPP-IV resistance, and C-terminal PEGylation and fatty acid derivatisation of incretins results in reduced renal clearance, by which several long-acting OXM analogues have been successfully developed (Muppidi et al., 2016). Indeed, a recent study of six novel OXM analogues has revealed that OXM-based peptides with specific N-terminal position 2 modifications are stable and show particular promise for the treatment of diabetes (Lynch et al., 2014). Moreover, a PEGylated analogue of OXM has also been designed and showed the long-lasting antihyperglycemic, insulinotropic and anorexigenic activity (Bianchi et al., 2013). In addition, Kerr et al also developed (d-Ser2)Oxm[mPEG-PAL], a novel OXM analogue with d-Ser at position 2 and C-16 palmitic acid conjugated via a mini-PEG linker at the C-terminus. And (d-Ser2)Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (d-Ser2)OXM and native OXM. Acute administration of (d-Ser2)Oxm[mPEG-PAL] and (d-Ser2)Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (d-Ser2)Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (d-Ser2)Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels (Kerr et al., 2010). In addition, several other forms of OXM including OXM6421 also showed similar effects (Pocai et al., 2009, Liu et al., 2010, Pocai, 2014).

**OXM in the brain**

Both OXM and GLP-1 are the anorexigenic gut hormones which are thought to physiologically regulate appetite and food intake in the brain (Vrang and Larsen, 2010). Most authors deemed that OXM and GLP-1 regulate appetite and food intake by activation GLP-1 receptor in the brain. Direct administration of OXM into the arcuate nucleus inhibits feeding and this effect is pharmacologically blocked by prior administration of the GLP-1 receptor antagonist exendin(9-39) (Dakin et al., 2004). Also, arcuate nucleus administration of OXM is accompanied by a decrease in plasma ghrelin, an appetite stimulating hormone, which in part could explain the drop in fasting- induced feeding elicited by central GLP-1 activation (Patterson et al., 2009). Thus, it seems likely that OXM mediates this activity via GLP-1 receptors. This is also supported by findings in GLP-R KO mice that are unresponsive to centrally administered OXM (Baggio et al., 2004) while glucagon receptor KO mice are responsive (Baggio et al., 2004). However, some researchers also showed a difference between GLP-1 and OXM activities. Administration of OXM resulted in a reduced rate of signal enhancement, reflecting in a reduction of neuronal activity in the arcuate, paraventricular, and supraoptic nuclei of the hypothalamus. Conversely, GLP-1 caused a reduction in signal enhancement in the paraventricular nucleus only and an increase in the ventromedial hypothalamic nucleus (Chaudhri et al., 2006). The results suggested that GLP-1 and OXM may also act via different pathways to exert their anorexigenic effects. Previously studies have shown that GLP-1 acts mainly via the vagus nerve and the brainstem (Abbott et al., 2005). Different from GLP-1, OXM may act via different hypothalamic pathways (Parkinson et al., 2009).

**The effects of OXM on neurodegenerative diseases**

Up to now, only two studies in vivo showed neuroprotective potential of OXM. A study in high fat (HF)
mice (Pathak et al., 2015) showed that (dS(2))Oxm(K-γ-glu-Pal) or (dS(2))Oxm treatment significant decrease hippocampal oxidative damage, enhance hippocampal neurogenesis and improve hippocampal and cortical synaptogenesis, besides improving peripheral glucose homeostasis metabolic. The results demonstrate the potential of stable OXM analogues to improve metabolic function and enhance neurogenesis, synaptic plasticity, insulin signaling and exert protective effects against oxidative damage in hippocampus and cortex brain regions in HF mice. Another study in vivo showed that D-Ser2-oxymontodulin (OXY) prevented or reversed motor impairment, reduction in tyrosine hydroxylase(TH) levels in the substantia nigra and basal ganglia and the reduction of the synaptic marker synapstophysin induced by MPTP (Liu et al., 2015b), which inidactes that OXM analogues may show promise as a novel treatment of PD.

**Dual agonist for GLP-1 and GIP receptors**

**Dual agonists and T2DM**

Together, GIP and GLP-1 account for almost all of the well-established physiological incretin effect and have powerful insulin-releasing and glucose-regulatory properties. Stable GLP-1 mimetics have already been successfully adopted into the diabetic clinic, and GIP also offer promise as potential new classes of antidiabetic drugs. So, a combination therapy of GIP and GLP-1 or use of dual agonist peptides for treating T2DM has been proposed. Indeed, the clinical benefits of DPP-4 inhibitors clearly involves increased circulating levels of both incretin peptides (Gallwitz, 2013), which demonstrates that concomitant activation of GIP and GLP-1 receptors does appear to have promise for the treatment of T2DM. Moreover, recent a study also demonstrated that a combined preparation of the acylated GLP-1 (Liraglutide) and GIP peptides (N-AcGIP(Lys(37)Myr)) markedly improved glucose-lowering and insulinoitropic properties in diabetic obesity compared with either incretin mimetic given individually (Gault et al., 2011). Therefore, dual agonist peptides for GLP-1R and GIP-R seem be more potent and beneficial than single receptor agonist for treatment T2DM (Irwin and Flatt, 2015).

Interestingly, a new drug DA-JC1, which is a dual-GLP-1/GIP receptor agonist derived from an intermixed sequence of GLP-1 and GIP, had been engineered to activate both GLP-1 and GIP receptors with comparable affinity, and demonstrated enhanced insulinoitropic and antihyperglycemic efficacy in animal models of diabetes relative to single GLP-1 agonist liraglutide (Finan et al., 2013). Moreover, the unimolecular dual incretin was DPP-IV-resistant, and maximized metabolic benefits and corrected two causal mechanisms of diabesity, adiposity-induced insulin resistance and pancreatic insulin deficiency (Finan et al., 2013). Furthermore, DA-JC1 balanced and avoided the adverse gastrointestinal effects that typify selective GLP-1-based agonists while showing effects at much lower doses than liraglutide.

**The effects of dual agonist on neurodegenerative diseases**

Given double receptor activation, dual agonist seem be more beneficial than single GLP-1 or GIP agonist for improvement insulin resistance of neurodegenerative Diseases. Currently, there are 2 published studies which demonstrated the neuroprotective effects of DA-JC1 in the MPTP mouse model of PD by increasing expression of BNDF (Ji et al., 2016b), increasing the number of TH- positive neurons in the SN and reducing the activation of astroglia and microglia (Cao et al., 2016). In addition, DA-JC1 also showed more neuroprotective effects than a GLP-1 receptor agonist in transient focal cerebral ischemia in the rat (Han et al., 2016). Hence, dual agonist for GLP-1R and GIP-R may be superior treatments for AD, PD and other neurodegenerative diseases based on their better insulinoitropic activity and neurotrophic activity (Ji et al., 2016a).
Triagonists for the GLP-1, GIP, and glucagon receptors

**Triagonists and T2DM**

GLP-1, GIP, and glucagon signaling are all comparatively important in terms of maintaining normal glycemic control (Cho et al., 2012). The G protein-coupled receptors (GPCRs) for GIP, GLP-1 and glucagon are emerging as targets to treat both hyperglycemia and obesity (Reimann and Gribble, 2016). Considering the evident therapeutic efficacy offered by dual agonist, single compounds with the ability to concurrently activate three regulatory peptide receptors could deliver even greater beneficial effects. Thus, there is now significant enthusiasm arising from designed peptides with the ability to concurrently modulate GIP, GLP-1 and glucagon receptor signaling.

Recently, several triple-acting peptides have been designed and showed dramatic improvements in glucose homeostasis and overall metabolic control in high fat fed mice (Finan et al., 2015). Bhat et al designed a chemically modified peptide based on human glucagon with amino acid substitutions aligned to strategic positions in the sequence of GIP and named YAG-glucagon. YAG-glucagon is Y(1)-dA(2)-I(12)-N(17)-V(18)-I(27)-G(28,29)-glucagon. YAG-glucagon is a DPP-IV-resistant triple agonist of GIP, GLP-1 and glucagon receptors and exhibits potent glucose-lowering and insulinotropic actions in high-fat-fed mice (Bhat et al., 2013b). Besides, the first 11 N-terminal residues of OXM were substituted with the sequence of stable d-Ala(2)GIP molecules to generate a novel GIP-OXM peptide (d-Ala(2)GIP-OXM). The novel GIP-OXM hybrid peptide also acts through GIP, glucagon and GLP-1 receptors. Acute administration of d-Ala(2)GIP-OXM to HFF mice resulted in reduced plasma glucose, increased insulin concentrations and reduced body weight (Bhat et al., 2013a). In addition, others (Gault et al., 2013) also have constructed a series of novel GLP-1/GIP/glucagon hybrid peptides, through fusion of the key amino acid sequences of GLP-1, GIP, and glucagon known to be important for biological activity. The most effective peptide of them is [dAla2]GLP-1-glucagon-GLP-1 ([dA2]GLP/GcG). [dA(2)]GLP-1/GcG stimulated cAMP production in GIP, GLP-1, and glucagon receptor-transfected cells. Acute and chronic administration of [dA(2)]GLP-1/GcG all significantly lowered plasma glucose and increased plasma insulin in obese diabetic (ob/ob) mice. Furthermore, [dA(2)]GLP-1/GcG elicited a protracted glucose-lowering and insulinotropic effect in high-fat-fed mice. [dA(2)]GLP-1/GcG decreased body weight, improved glucose tolerance and insulin sensitivity in high fat -fed mice. These findings showed that a unimolecular triple agonism strategy has potential to be the most effective pharmacological approach to reversing obesity and related metabolic disorders (Finan et al., 2015). Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis. These dramatic effects may predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.

**Effects of triagonist on neurodegenerative Diseases**

In view of dual agonist having shown good promising for AD and PD, novel triagonists that activate GLP-1, GIP and glucagon receptors and that are currently being developed to treat type II diabetes (Finan et al., 2015) should be tested in a variety of neurodegenerative disease models to investigate if they have superior properties to dual or single receptor agonists.

**Conclusion**

Neurodegenerative diseases and T2DM share common mechanisms, such as insulin resistance, which have
motivated the application of incretin hormones as a treatment of neurodegenerative diseases. Among incretin-based therapy, GLP-1 long-acting analogous not only have demonstrated promising effects in neurodegenerative diseases in preclinical studies, but also have shown first promising results in AD and PD patients in clinical trials. The effects of other related incretin-based therapies, such as GIP agonists, DPP-IV inhibitors, OXM, dual agonists and triagonists for incretin receptors on neurodegenerative diseases have been tested in preclinical studies. As novel dual or tri agonists appear to be superior to single agonists, dual or tri agonists are becoming the focus of research. Incretin-based therapies may show great promise of being helpful in treating a range of neurodegenerative disorders. However, clinical trials testing the effects in patients with neurodegenerative disorders will have to be initiated to test what the actual benefits will be.

References


neurosciences 18:223-251.


Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES,
incretin drugs can treat neurodegenerative diseases


incretin drugs can treat neurodegenerative diseases

the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus. Peptides 32:781-789.


Gault VA, Holscher C (2008a) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. European journal of pharmacology 587:112-117.

incretin drugs can treat neurodegenerative diseases


incretin drugs can treat neurodegenerative diseases


Irwin N, Flatt PR (2015) New perspectives on exploitation of incretin peptides for the treatment of diabetes and...
Incretin drugs can treat neurodegenerative diseases.


Kanbe HM, Sharp PS, Rahmani-Kondori N, Wells DJ (2011) Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PloS one 6:e24189.


Lekoubou A, Matsha TE, Sobngwi E, Kengne AP (2014) Effects of diabetes mellitus on amyotrophic lateral sclerosis:
incretin drugs can treat neurodegenerative diseases

a systematic review. BMC research notes 7:171.
Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010b) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. Journal of neurochemistry 113:1621-1631.
Luchsinger JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. Journal of Alzheimer's disease :
Incretin drugs can treat neurodegenerative diseases


incretin drugs can treat neurodegenerative diseases


incretin drugs can treat neurodegenerative diseases

incretin drugs can treat neurodegenerative diseases


incretin drugs can treat neurodegenerative diseases


**incretin drugs can treat neurodegenerative diseases**

**Fig. 1:** Chemical modifications of GLP-1R agonists compared in head-to-head studies. The figure illustrates how different strategies have been applied to the GLP-1R agonists in order to provide prolonged action in the body. Grey circles indicate an altered amino acid sequence compared to native GLP-1. a. Exenatide once-weekly: the exenatide molecules are encapsulated in injectable microspheres. Abbreviations: rH-Albumin, recombinant human albumin; IgG Fc fragment, immunoglobulin fragment crystallized (Lund et al., 2014).

**Table 1:** GLP-1R agonists clinically approved or not yet approved (Lund et al., 2014)

<table>
<thead>
<tr>
<th>name</th>
<th>the trade name</th>
<th>half-life</th>
<th>administration</th>
<th>company</th>
<th>approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exenatide</td>
<td>Byetta®</td>
<td>2 to 3 h</td>
<td>Subcutaneous twice-daily</td>
<td>Bristol Myers Squibb-AstraZeneca</td>
<td>USFDA, 2005, Europe, 2006</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>Victoza®</td>
<td>11 to 15 h</td>
<td>Subcutaneous once-daily</td>
<td>Novo Nordisk</td>
<td>EU, Japan, 2009, USFDA, 2010</td>
</tr>
<tr>
<td>Lixisenatide</td>
<td>Lyxumia®</td>
<td>2 to 3 h</td>
<td>Subcutaneous once-daily</td>
<td>Sanofi</td>
<td>Europe February 2013</td>
</tr>
<tr>
<td>Taspoglutide</td>
<td></td>
<td></td>
<td>Subcutaneous once weekly</td>
<td>Ipsen/Roche</td>
<td></td>
</tr>
</tbody>
</table>
Incretin drugs can treat neurodegenerative diseases

<table>
<thead>
<tr>
<th>Incretin Drugs</th>
<th>Trade Names</th>
<th>Half-Life (Hrs)</th>
<th>Route of Administration</th>
<th>Manufacturer</th>
<th>Approval Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albiglutide</td>
<td>Eperzan® (EU), Tanzeum® (US)</td>
<td>5 to 8 days</td>
<td>Subcutaneous once-weekly</td>
<td>GlaxoSmithKline</td>
<td>Europe and USFDA, 2014</td>
</tr>
<tr>
<td>Dulaglutide</td>
<td>Trulicity™ (LY2189265)</td>
<td>approximately 90 h</td>
<td>Subcutaneous once-weekly</td>
<td>Eli Lilly</td>
<td>Europe and USFDA, 2014</td>
</tr>
<tr>
<td>Semaglutide</td>
<td>165 h</td>
<td>Subcutaneous once-weekly</td>
<td>Novo Nordisk</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>